Pharmacological Aids for Interactive Smoking Cessation (NRT_2)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02329249|
Recruitment Status : Completed
First Posted : December 31, 2014
Last Update Posted : January 1, 2015
|Condition or disease||Intervention/treatment||Phase|
|Smoking Cessation||Behavioral: Smokefree Partners: 21 Days to Freedom Other: Wait-List Control||Not Applicable|
The Smokefree Partners: 21 Days to Freedom combined online video, text, and interactive tools to promote the effective use of pharmacological aids (PA) — nicotine replacement products and bupropion (Zyban®) — and provide cognitive-behavioral support for users as they attempted to stop smoking. Smoking cessation content was based on the U.S. Surgeon General's Clinical Guidelines, Treating Tobacco Use and Dependence, 2008 update. Presentation of some of the content (e.g., gender of the narrator, PA recommendations) was tailored to the user on demographic and smoking history information provided during registration and within the introductory session.
Two critical features provided social support and accountability. First, each user was assigned a "live" smoking cessation coach to provide support via individually tailored phone or email contacts (contact preference specified by the user). Users also received automated email reminders and prompts from the program. Second, a bulletin board/forum feature was added to promote social support among users.
The Smokefree Partners intervention was a multi-session intervention in which users experienced a controlled and scheduled exposure to 21 discrete web site sessions. The program required users to wait at least 10 hours between sessions (i.e., login was "locked" until 10 hours had passed after a user's previous Web site session). Carefully timed and tailored coaching messages provided cessation tips and prompted users to return to the web site to view the next session.
The program was evaluated online in a randomized clinical trial of smokers recruited through major worksites across the United States. The aim of the evaluation was to determine if a theoretically based, online smoking cessation program that included message tailoring and interactivity combined with the live personal support of a coach would result in improved quit rates when compared to a wait-list control condition.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||500 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Pharmacological Aids for Interactive Smoking Cessation|
|Study Start Date :||February 2001|
|Actual Primary Completion Date :||January 2005|
|Actual Study Completion Date :||January 2006|
Experimental: Smokefree Partners: 21 Days to Freedom
Smoking cessation website program with live personal coach
Behavioral: Smokefree Partners: 21 Days to Freedom
Treatment subjects, who chose a quit date, were given 21 sessions to be viewed one session (i..e, one day) at a time, and an in-person smoking cessation coach to support them through their quit process via tailored email or phone coaching messages. Treatment users were encouraged to use pharmacological aids in their quit attempt, but smoking cessation aids were not provided.
Other Name: Pharmacological Aids for Interactive Smoking Cessation
120-day wait-list and then provided access to the smoking cessation website
Other: Wait-List Control
Subjects randomized to the control condition were placed on a wait-list and given access to the smoking cessation program after 120 days and completion of the 120-day follow-up assessment.
- Smoking cessation [ Time Frame: 120 days ]Current smoking status was determined with two items: (a) a stage of change measure indicating smoking status and (b) a measure indicating the number of cigarettes smoked in the past 7 days. Abstinence at 30-day posttest and 120-day follow-up was confirmed by the participant choosing both (a) the response of "I do not currently smoke; I quit in the last 6 months" to the stage of change measure and (b) a response of "0" to the question "During the past 7 days, how many cigarettes did you smoke each day?"
- Intentions to quit smoking [ Time Frame: 30 days and 120 days after baseline ]1 item assessing the user's likelihood of quitting smoking within the next 30 days; 1-5 response scale (1=extremely likely, 5=not at all likely)
- intentions to quit and remain smokefree [ Time Frame: 30 days and 120 days after baseline ]1 item assessing the likelihood of quitting and remaining smokefree; 1-5 response scale (1=extremely likely, 5=not at all likely)
- self-efficacy for quitting [ Time Frame: 30 days and 120 days after baseline ]2 items assessing the user's confidence to (a) quit smoking and (b) quit and remain smokefree; 1-5 response scale (1=extremely confident, 5=not at all confident)
- intentions to use a pharmacological smoking cessation aid (PA) [ Time Frame: 30 days and 120 days after baseline ]2 items assessing the user's intention to use (a) a nicotine replacement product or (b) Zyban during this quit attempt; 1-5 response scale (1=extremely likely, 5=not at all likely)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02329249
|Principal Investigator:||Susan Schroeder, MPH, MCHES||Oregon Center for Applied Science|